Plain-English translation of NCT06594783 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether people with cirrhosis (severe liver disease) who aren't responding well enough to carvedilol medication alone should also receive an endoscopic procedure called variceal ligation. Carvedilol is a blood pressure medication that helps reduce dangerous pressure in the blood vessels of the esophagus (food pipe). The trial compares continuing versus combining it with regular endoscopic procedures to seal off enlarged veins before they can bleed.
Many people with liver disease develop enlarged veins in the esophagus that can rupture and cause life-threatening bleeding. While this medication works for some patients, up to half of people don't respond well enough to the drug alone, and doctors aren't sure what the best additional treatment should be for them.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: either continue taking carvedilol daily, or take carvedilol daily and also receive endoscopic procedures every 3–4 weeks to treat the enlarged veins. Both groups will start with a low dose of the medication (6.25 mg per day) which may be increased to 12.5 mg per day based on how you tolerate it. If you're in the procedure group, you'll have upper endoscopy visits every few weeks until the veins are gone, then have regular follow-up endoscopies to monitor your condition. The trial will track whether bleeding occurs and how well each approach prevents complications.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Taiwan